Medifast’s second quarter was marked by stabilization in key business metrics despite continued pressure from declining coach numbers and shifting industry trends. The company’s revenue and earnings surpassed Wall Street expectations, contributing to a strong positive market reaction. Management credited improved coach productivity—up for the third consecutive quarter—and the early impact of its new consumer brand, Trilivy, as key drivers of sequential stabilization. CEO Nick Johnson highlighted, “Coach productivity was positive for the third straight quarter, with the highest revenue per active earning coach since 2022.”
Is now the time to buy MED? Find out in our full research report (it’s free for active Edge members).
Medifast (MED) Q2 CY2026 Highlights:
- Revenue: $76.38 million vs analyst estimates of $72.7 million (27.6% year-on-year decline, 5.1% beat)
- EPS (GAAP): -$0.28 vs analyst estimates of -$0.65 (56.9% beat)
- The company reconfirmed its revenue guidance for the full year of $285 million at the midpoint
- EPS (GAAP) guidance for the full year is -$1 at the midpoint, beating analyst estimates by 39%
- Operating Margin: -5.7%, down from -1% in the same quarter last year
- Market Capitalization: $130.5 million
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Medifast’s Q2 Earnings Call
-
Jim Salera (Stephens Inc.) asked for details on the Catalyst program’s implementation costs and expected savings. CFO Jim Maloney replied that while millions in annual savings are targeted, specifics will be disclosed in the next quarter as the company finalizes plans.
-
Jim Salera (Stephens Inc.) questioned whether the path to profitability in Q4 2026 relies solely on Catalyst or if other factors contribute. Maloney emphasized both cost savings from Catalyst and top-line stabilization, reinforced by new product launches, as key levers.
-
Jim Salera (Stephens Inc.) inquired about coach receptivity to the Trilivy rollout and any transition challenges. CEO Nick Johnson reported overwhelmingly positive feedback from the field, with no major issues observed during the shift from OPTAVIA.
-
Jim Salera (Stephens Inc.) asked how new products and compensation changes might impact margins. Maloney explained that top-line stabilization and cost actions should improve margins, with further benefits as the business grows and fixed costs are leveraged.
-
Jim Salera (Stephens Inc.) probed for clarity on future margin trajectory as coach productivity rises. Maloney reiterated that increasing productivity historically leads to coach and revenue growth, which should positively impact fixed cost leverage over time.
Catalysts in Upcoming Quarters
Looking to the rest of the year, the StockStory team will be monitoring (1) the impact of the Trilivy brand and new product launches on client and coach retention, (2) the pace and effectiveness of cost savings under the Catalyst initiative, and (3) ongoing trends in coach productivity as a precursor to potential revenue growth. Execution on these milestones will be critical to assessing progress toward profitability.
Medifast currently trades at $12.64, up from $9.74 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
